Merus Labs International Inc. Form 6-K December 21, 2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of **December 2011**

Commission File No. <u>00-30082</u>

MERUS LABS INTERNATIONAL INC.

(formerly Envoy Capital Group Inc.)

(Translation of registrant's name into English)

Suite 2007, 1177 West Hastings Street Vancouver, BC V6E 2K3

(Address of principal executive office)

Form 20-F [X] Form 40-F []
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) []
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule $101(b)(7)$ []
Indicate by check mark whether the registrant, by furnishing the information contained in this Form, is also thereby furnishing the information to the Commission pursuant to Rule $12g3-2(b)$ under the Securities Exchange Act of 193 Yes [] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 1293-2(b):

82-_

- 2 -

SUBMITTED HEREWITH

Exhibits

Exhibit	Description
No.	
<u>99.1</u>	Annual Report
<u>99.2</u>	Annual Financial Statements
99.2 99.3	Management Discussion and Analysis
<u>99.4</u>	News Release dated December 20, 2011
<u>99.5</u>	Material Change Report dated December 21, 2011
<u>99.6</u>	Certificate of Amalgamation
<u>99.7</u>	National Instrument 51-102 - Change in Corporate Structure

Edgar Filing: Merus Labs International Inc. - Form 6-K

- 3 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: December 21, 2011

MERUS LABS INTERNATIONAL INC.

/s/ Andrew Patient Andrew Patient Chief Financial Officer